Platform

Rethinking What Medicine Should Be

In the near future, your doctor may prescribe you drugs made of live bacterial consortia. These drugs have the potential of colonizing the human intestine naturally and repairing microbiome alterations that drive disease.

How Our Drugs Work

Why bacterial consortia?

Unlike fecal transplants, which require use of donors and are an untargeted, inherently variable procedure, bacterial consortia therapeutics are defined drug compositions produced from clonally isolated bacteria that can trigger targeted immune responses. And unlike reductionistic approaches such as single strain probiotics, they can robustly shift the gut ecosystem.

Step One:

Oral Administration in Capsule Form

Step Two:

Colonization of the Intestine

The active ingredients travel down the gastrointestinal tract and colonize the intestine. Unlike probiotics, our drugs are based on the dominant, most abundant dwellers of the human intestine. They can shift the composition of the gut microbiota and provide colonization resistance against a range of intestinal infectious pathogens.

Step Three:

Stimulation of Targeted Immune Responses

Our drugs can stimulate a range of immune responses ranging from immunoregulatory responses, which hold potential in the treatment of autoimmune and allergic diseases, to immunopotentiating responses, which hold potential in cancer and vaccination.